Three Aussie Drug Distributors See $1 Billion Loss By Pfizer Switch
This article was originally published in PharmAsia News
Executive Summary
Australia's Symbion and Australian Pharmaceutical Industries say they expect to lose big chunks of revenue due to U.S.-based Pfizer's self-distribution plan in the country